

CERTIFICATE OF EFS FILING UNDER 37 CFR §1.8

I hereby certify that this correspondence is being electronically transmitted to the United States Patent and Trademark Office, Commissioner for Patents, via the EFS pursuant to 37 CFR §1.8 on the below date:

Date: January 9, 2008 Name: Magdalena O. Cilella, Ph.D. Signature: /Magdalena O. Cilella, Reg. No. 56,619/

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Zheng Wei

Serial No.: 10/630,180

Filing Date: July 30, 2003

For: METHOD FOR MULTIPLE CHEMOKINE
RECEPTOR SCREENING FOR
ANTAGONISTS USING RAM ASSAY

Examiner: DeBerry, Regina M.

Group Art Unit No.: 1647

SEVENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and §§1.97-1.98, and more particularly in accordance with 37 C.F.R. §1.97(d), Applicant hereby cites the following reference:

OTHER ART – NON PATENT LITERATURE DOCUMENTS

Ali, H., et al., "Chemoattractant Receptor Cross-desensitization," *The Journal of Biological Chemistry*, 274(10):6027-30 (1999)

Applicant is enclosing Form PTO-1449 (one sheet), along with a copy of each listed reference for which a copy is required under 37 C.F.R. §1.98(a)(2). As the above listed reference is in English, no further commentary is believed to be necessary, 37 C.F.R. §1.98(a)(3). Applicant respectfully requests the Examiner's consideration of the above reference and entry thereof into the record of this application.

By submitting this Statement, Applicant is attempting to fully comply with the duty of candor and good faith mandated by 37 C.F.R. §1.56. As such, this Statement is not

intended to constitute an admission that the enclosed reference, or other information referred to therein, constitutes "prior art" or is otherwise "material to patentability," as that phrase is defined in 37 C.F.R. §1.56(a).

Pursuant to 37 C.F.R. §1.97(e)(2), Applicant certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. Applicant has also calculated a processing fee in the amount of \$180.00 to be due under 37 C.F.R. §1.17(p) in connection with the filing of this Information Disclosure Statement. Applicant has enclosed a check covering this fee, or authorized charging the fee to a deposit account or credit card, as indicated in the Transmittal accompanying this Information Disclosure Statement.

Respectfully submitted,

January 9, 2007

Date

/Magdalena O. Cilella, Reg. No. 56,619/

Magdalena O. Cilella, Ph.D.
(Reg. No. 56,619)